Shares of Neurocrine Biosciences surged Thursday after drug development partner AbbVie said their potential treatment for endometriosis-related pain fared well in late-stage research. AbbVie said early results from the first of two phase three studies of the drug showed that doses of elagolix met the study's main goals of reducing non-menstrual pelvic pain and menstrual pain in patients with endometriosis.